Email
Print
Acute Lymphocytic/Lymphoblastic Leukemia Market - Forecast(2024 - 2030)
Acute Lymphocytic/Lymphoblastic Leukemia Market Overview
Acute Lymphocytic/Lymphoblastic Leukemia Market is set to register a CAGR of 5.3% and a market value of $3,650 million in 2020 over the forecast period of 2021-2026. Acute Lymphocytic/Lymphoblastic Leukemia is a type of cancer that affects white blood cells by developing large number of immature lymphocytes. Acute lymphocytic leukemia develops quickly among young children. Chemotherapy is mostly used for the treatment of acute lymphocytic leukemia disease in order to destroy the cancer cells. Leukemia cells build up in the blood and bone marrow that reduces the space for healthy white blood cells which causes infection, anemia, and easy bleeding. Li-Fraumeni syndrome is a disorder that mostly occur among children and young adults and increasing the risk of breast cancer, brain tumors, and many more. The central nervous system involvement is common in acute lymphoblastic leukemia and about 5% of adults have CNS (central nervous system) at initial diagnosis. Nucleosides are considered metabolic inhibitors which are a kind of drug for the treatment of leukemia. Recently, linker regimen are also recommended for the treatment of acute lymphocytic/lymphoblastic leukemia. The surging number of cancer cases among people increases the awareness for the early diagnosis of acute leukemia which enhances the growth of the acute lymphocytic leukemia market. Moreover, growing government initiatives for adopting advanced cancer therapies for detecting affected cells helps patients to prevent cancer which is the major factor driving the growth of Acute Lymphocytic/Lymphoblastic Market. Furthermore, rising investments in research and development activities for developing technologies help in enhancing the overall market demand for Acute Lymphocytic/Lymphoblastic Market for the period 2021-2026.
Covid-19 Impact:
COVID-19 pandemic had greatly impacted the growth of Acute Lymphocytic/Lymphoblastic Leukemia Market. During pandemic, healthcare institutes are completely focused on covid infected patients. This factor reduces the use of a variety of cancer therapies such as chemotherapy, radiotherapy, and many more and is negatively impacted the growth of Acute Lymphocytic/Lymphoblastic Leukemia Market.
Acute Lymphocytic/Lymphoblastic Leukemia Market Report Coverage
The report: “Acute Lymphocytic/Lymphoblastic Leukemia Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis of the following segments of the Acute Lymphocytic/Lymphoblastic Market.
By Type: B-Cell ALL, T-Cell ALL, and Philadelphia Chromosome
By Therapy: Chemotherapy, Radiation Therapy, Targeted Therapy and Stem Cell Transplant
By Geography: North America (U.S., Canada, Mexico), Europe (U.K, Germany, Italy, France, Spain, Russia, Rest of Europe), Asia Pacific (China, Australia, Japan, South Korea, India, Rest of Asia Pacific), South America (Brazil, Argentina, Others) and Rest of the World (Middle East, Africa)
Key Takeaways
- In 2020, North America dominated the Acute Lymphocytic/Lymphoblastic Leukemia Market. This is owing to soaring advancements in technology that improve the treatment for acute lymphocytic leukemia. Moreover, a large number of companies are developing a variety of drugs for the diagnosis of leukemia disease which is growing the production of drugs for leukemia diseases. This factor enlarges the growth in Acute Lymphocytic/Lymphoblastic Leukemia Market.
- Surging number of cancer cases among people increases awareness for the early diagnosis of acute leukemia which enhances the growth of acute lymphocytic leukemia market. Moreover, growing government initiatives for adopting advanced cancer therapies for detecting affected cells helps patients to prevent from cancer and thus improving the growth of the Acute Lymphocytic/Lymphoblastic Leukemia Market.
- The prominent manufacturers operating in the market will be provided detailed analysis of Strength, Weakness, and Opportunities in the Acute Lymphocytic/Lymphoblastic Leukemia Market report.
- High cost of treatment for leukemia disease create hurdles for the Acute Lymphocytic/Lymphoblastic Leukemia Market.
Acute Lymphocytic/Lymphoblastic Leukemia Market Size, By Therapy 2020
For More Details on This Report - Request for Sample
Acute Lymphocytic/Lymphoblastic Leukemia Segment Analysis – By Type
The Acute Lymphocytic/Lymphoblastic Leukemia Market based on Type can be further distributed into B-Cell ALL, T-Cell ALL, and Philadelphia Chromosome. The B-Cell segment is the major segment generating revenue in 2020. This is mainly owing to the fact that B-Cell Leukemia mostly occur among children that surge the need of various cancer therapies such as chemotherapy, radiation therapy, and many more. This factor enlarges the advancement in B-Cell ALL treatment which further expand the growth in Acute Lymphocytic Leukemia Market. The T-Cell ALL segment is estimated to register the fastest CAGR of 5.9% for the period 2021-2026. T-cell acute lymphocytic leukemia represents approximately 12% of all newly diagnosed cases in pediatric patients that increases the developments for the treatment of T-CELL acute lymphocytic disease and further propell the growth of Acute Lymphocytic/Lymphoblastic Leukemia Market.
Acute Lymphocytic/Lymphoblastic Leukemia Segment Analysis – By Therapy
The Acute Lymphocytic/Lymphoblastic Leukemia Market based on Therapy can be further segmented into Chemotherapy, Radiation Therapy, Targeted Therapy and Stem Cell Transplant. The Chemotherapy segment registers for the highest Acute Lymphocytic/Lymphoblastic Leukemia Market share in 2020. This is owing to its effective results in acute leukemia that enhance the adoption of chemotherapy. Moreover, the adoption of chemotherapy increased by 14% in 2019 owing to the surging adoption of chemotherapy in various healthcare centers as it provides more quick results which hike the need of chemotherapy. The Radiation Therapy segment is forecasted to register the fastest CAGR of 6.1% over 2021-2026. Radiation therapy provides more control to stop the development of cancer cells that is rising the preference among patients. In T-Cell acute lymphocytic leukemia, the need of radiation therapy increases which propelles the growth of Acute Lymphocytic/Lymphoblastic Leukemia Market.
Acute Lymphocytic/Lymphoblastic Leukemia Segment Analysis – By Geography
North America dominated the Acute Lymphocytic/Lymphoblastic Leukemia Market with a major share of 40% in 2020. This is owing to soaring advancements in technology that improve the treatment for acute lymphocytic leukemia. Moreover, the large number of companies are developing a variety of drugs for the diagnosis of leukemia disease which spikes the production of drugs for leukemia diseases. This factor enlarges the growth in Acute Lymphocytic/Lymphoblastic Leukemia Market. Recently, next-generation targeted therapies, molecular cancer diagnostics, artificial intelligence based therapy design is mostly used in U.S. for the treatment of acute lymphocytic leukemia treatment that further boost the market growth.
However, Asia Pacific is projected to be the growing market during the forecast period 2021-2026 owing to rising cases of cancer the encourage the use of chemotherapy. In India, 30-35% of people are adopting chemotherapy which further enlarging the growth in Acute Lymphocytic/Lymphoblastic Leukemia Market.
Acute Lymphocytic/Lymphoblastic Leukemia Market Drivers
Surging number of cancer cases among people increases awareness for the early diagnosis of acute leukemia which enhance the growth of acute lymphocytic leukemia market
The number of cancer cases soaring among people which is creating awareness for the early diagnosis of acute leukemia that enhance the growth of acute lymphocytic/lymphoblastic leukemia market. In 2020, about 10% of world population are suffering from acute lymphocytic leukemia diseases where the incidence of ALL (acute lymphocytic leukemia) ranges from 0.4 to 2 per 100,000 in the Asia Pacific. This factor encourages the awareness among patients to adopt early diagnosis which further drives the demand of Acute Lymphocytic/Lymphoblastic Leukemia Market over the period 2021-2026.
Growing government initiatives encourage manufacturers to adopt advanced cancer therapies for detecting affected cells and help patients to prevent from cancer which is the major factor driving the growth of Acute Lymphocytic/Lymphoblastic Market
Various government organization such as American Cancer Society, National Cancer Institute are taking initiatives to organize campaign where various advanced cancer therapies are used for detecting the cancer cells that helps patients to get rid from cancer. Government is also providing funds to various healthcare institute that helps healthcare manufacturers to develop the technologies and innovating drugs for the treatment of cancer. This factor boost the demand of Acute Lymphocytic/Lymphoblastic Leukemia Market over the period 2021-2026.
Acute Lymphocytic/Lymphoblastic Leukemia Market Challenges
High cost of treatment for leukemia disease create hurdles for the Market
The factors that are set to affect the growth of the market are the high cost of treatment for leukemia disease. In India, the cost of leukemia treatment ranging from $7,000-$18,000 in hospitals which is very expensive and not affordable among many patients is set to challenge the market of Acute Lymphocytic/Lymphoblastic Leukemia.
Market Landscape
Product launches, acquisitions, collaboration, joint ventures, and geographical expansions are key strategies adopted by players in the Acute Lymphocytic/Lymphoblastic Leukemia Market. Acute Lymphocytic/Lymphoblastic Leukemia top 10 companies are
1. GlaxoSmithKline Plc.
2. Pfizer Inc.
3. Novartis AG
4. Genzyme Corporation
5. Erytech Pharma
6. Celgene Corporation
7. Jazz Pharmaceuticals
8. Spectrum Pharmaceuticals Inc.
9. Sanofi
10. Leadiant Biosciences Inc.
Development
In 2020, Jazz Pharmaceuticals initiated the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval for JZP-458 for the treatment of acute lymphoblastic leukemia (ALL).
Relevant Reports:
Report Code: HCR 0195
Report Code: HCR 24112
For more Lifesciences and Healthcare Market reports, please click here
1. Acute Lymphocytic/Lymphoblastic Leukemia Market Overview
1.1 Definitions and Scope
2. Acute Lymphocytic/Lymphoblastic Leukemia Market Executive Summary
2.1 Market Size and Key Trends
2.2 Key trends by Type
2.3 Key trends by Therapy
2.4 Key trends by Geography
3. Acute Lymphocytic/Lymphoblastic Leukemia Market Landscape
3.1 Market Share Analysis- Key Companies
3.2 Product Benchmarking- Key Companies
3.3 Financial Analysis - Key Companies
3.4 Patent Analysis
3.5 Pricing Analysis
4. Acute Lymphocytic/Lymphoblastic Leukemia Market- Startup companies Scenario Premium Premium
4.1 Key startup company Analysis by
4.1.1 Investment
4.1.2 Revenue
4.1.3 Application Analysis
4.1.4 Venture Capital and Funding Scenario
5. Acute Lymphocytic/Lymphoblastic Leukemia Market- Industry Market Entry Scenario Premium Premium
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case Studies of successful ventures
6. Acute Lymphocytic/Lymphoblastic Leukemia Market Forces
6.1 Market Drivers
6.2 Market Constraints/Challenges
6.3 Porters Five Force Model
6.3.1 Bargaining Power of Suppliers
6.3.2 Bargaining Powers of Customers
6.3.3 Threat of New Entrants
6.3.4 Rivalry Among Existing Players
6.3.5 Threat of Substitutes
7. Acute Lymphocytic/Lymphoblastic Leukemia Market Strategic Analysis
7.1 Value Chain Analysis
7.2 Opportunities Analysis
7.3 Market Life Cycle
8. Acute Lymphocytic/Lymphoblastic Leukemia Market– By Type (Market Size -$Million/$Billion)
8.1 B-Cell ALL
8.2 T-Cell ALL
8.3 Philadelphia Chromosome
9. Acute Lymphocytic/Lymphoblastic Leukemia Market– By Therapy (Market Size -$Million/$Billion)
9.1 Chemotherapy
9.2 Radiation Therapy
9.3 Targeted Therapy
9.4 Stem Cell Transplant
10. Acute Lymphocytic/Lymphoblastic Leukemia Market- By Geography (Market Size -$Million/$Billion)
10.1 North America
10.1.1 U.S.
10.1.2 Canada
10.1.3 Mexico
10.2 Europe
10.2.1 U.K.
10.2.2 Germany
10.2.3 Italy
10.2.4 France
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Asia-Pacific
10.3.1 China
10.3.2 Australia
10.3.3 Japan
10.3.4 South KoreaText Box: 06
10.3.5 India
10.3.6 Rest of Asia-Pacific
10.4 South America
10.4.1 Brazil
10.4.2 Argentina
10.4.3 Others
10.5 Rest of the World
10.5.1 Middle East
10.5.2 Africa
11. Acute Lymphocytic/Lymphoblastic Leukemia Market Entropy
12. Acute Lymphocytic/Lymphoblastic Leukemia Market- Industry / Segment Competition landscape Premium Premium
12.1 Market Share Analysis
12.1.1 Market Share by Country- Key companies
12.1.2 Market Share by Region- Key companies
12.1.3 Market Share at Global Level- Key companies
12.1.4 Competition Matrix
12.1.5 Best Practices for Companies
13. Acute Lymphocytic/Lymphoblastic Leukemia Market- Key Company List by Country Premium Premium
14. Acute Lymphocytic/Lymphoblastic Leukemia Market Company Analysis
14.1 Company Revenue, Products, M&A, Developments
14.2 Company 1
14.3 Company 2
14.4 Company 3
14.5 Company 4
14.6 Company 5
14.7 Company 6
14.8 Company 7
14.9 Company 8
14.10 Company 9
14.11 Company 10
"*Financials for private companies would be provided on a best efforts basis”.
LIST OF TABLES
1.Global ACUTE LYMPHOCYTIC LEUKEMIA MARKET, BY TYPE Market 2023-2030 ($M)1.1 Pediatric Market 2023-2030 ($M) - Global Industry Research
1.2 Adult Market 2023-2030 ($M) - Global Industry Research
2.Global ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG Market 2023-2030 ($M)
2.1 Overvie Market 2023-2030 ($M) - Global Industry Research
2.2 Hyper-CVAD regimen Market 2023-2030 ($M) - Global Industry Research
2.3 Linker regimen Market 2023-2030 ($M) - Global Industry Research
2.4 Nucleoside metabolic inhibitors Market 2023-2030 ($M) - Global Industry Research
2.6 CALGB 8811 regimen Market 2023-2030 ($M) - Global Industry Research
2.7 Oncaspar Market 2023-2030 ($M) - Global Industry Research
3.Global ACUTE LYMPHOCYTIC LEUKEMIA MARKET, BY TYPE Market 2023-2030 (Volume/Units)
3.1 Pediatric Market 2023-2030 (Volume/Units) - Global Industry Research
3.2 Adult Market 2023-2030 (Volume/Units) - Global Industry Research
4.Global ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG Market 2023-2030 (Volume/Units)
4.1 Overvie Market 2023-2030 (Volume/Units) - Global Industry Research
4.2 Hyper-CVAD regimen Market 2023-2030 (Volume/Units) - Global Industry Research
4.3 Linker regimen Market 2023-2030 (Volume/Units) - Global Industry Research
4.4 Nucleoside metabolic inhibitors Market 2023-2030 (Volume/Units) - Global Industry Research
4.6 CALGB 8811 regimen Market 2023-2030 (Volume/Units) - Global Industry Research
4.7 Oncaspar Market 2023-2030 (Volume/Units) - Global Industry Research
5.North America ACUTE LYMPHOCYTIC LEUKEMIA MARKET, BY TYPE Market 2023-2030 ($M)
5.1 Pediatric Market 2023-2030 ($M) - Regional Industry Research
5.2 Adult Market 2023-2030 ($M) - Regional Industry Research
6.North America ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG Market 2023-2030 ($M)
6.1 Overvie Market 2023-2030 ($M) - Regional Industry Research
6.2 Hyper-CVAD regimen Market 2023-2030 ($M) - Regional Industry Research
6.3 Linker regimen Market 2023-2030 ($M) - Regional Industry Research
6.4 Nucleoside metabolic inhibitors Market 2023-2030 ($M) - Regional Industry Research
6.6 CALGB 8811 regimen Market 2023-2030 ($M) - Regional Industry Research
6.7 Oncaspar Market 2023-2030 ($M) - Regional Industry Research
7.South America ACUTE LYMPHOCYTIC LEUKEMIA MARKET, BY TYPE Market 2023-2030 ($M)
7.1 Pediatric Market 2023-2030 ($M) - Regional Industry Research
7.2 Adult Market 2023-2030 ($M) - Regional Industry Research
8.South America ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG Market 2023-2030 ($M)
8.1 Overvie Market 2023-2030 ($M) - Regional Industry Research
8.2 Hyper-CVAD regimen Market 2023-2030 ($M) - Regional Industry Research
8.3 Linker regimen Market 2023-2030 ($M) - Regional Industry Research
8.4 Nucleoside metabolic inhibitors Market 2023-2030 ($M) - Regional Industry Research
8.6 CALGB 8811 regimen Market 2023-2030 ($M) - Regional Industry Research
8.7 Oncaspar Market 2023-2030 ($M) - Regional Industry Research
9.Europe ACUTE LYMPHOCYTIC LEUKEMIA MARKET, BY TYPE Market 2023-2030 ($M)
9.1 Pediatric Market 2023-2030 ($M) - Regional Industry Research
9.2 Adult Market 2023-2030 ($M) - Regional Industry Research
10.Europe ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG Market 2023-2030 ($M)
10.1 Overvie Market 2023-2030 ($M) - Regional Industry Research
10.2 Hyper-CVAD regimen Market 2023-2030 ($M) - Regional Industry Research
10.3 Linker regimen Market 2023-2030 ($M) - Regional Industry Research
10.4 Nucleoside metabolic inhibitors Market 2023-2030 ($M) - Regional Industry Research
10.6 CALGB 8811 regimen Market 2023-2030 ($M) - Regional Industry Research
10.7 Oncaspar Market 2023-2030 ($M) - Regional Industry Research
11.APAC ACUTE LYMPHOCYTIC LEUKEMIA MARKET, BY TYPE Market 2023-2030 ($M)
11.1 Pediatric Market 2023-2030 ($M) - Regional Industry Research
11.2 Adult Market 2023-2030 ($M) - Regional Industry Research
12.APAC ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG Market 2023-2030 ($M)
12.1 Overvie Market 2023-2030 ($M) - Regional Industry Research
12.2 Hyper-CVAD regimen Market 2023-2030 ($M) - Regional Industry Research
12.3 Linker regimen Market 2023-2030 ($M) - Regional Industry Research
12.4 Nucleoside metabolic inhibitors Market 2023-2030 ($M) - Regional Industry Research
12.6 CALGB 8811 regimen Market 2023-2030 ($M) - Regional Industry Research
12.7 Oncaspar Market 2023-2030 ($M) - Regional Industry Research
13.MENA ACUTE LYMPHOCYTIC LEUKEMIA MARKET, BY TYPE Market 2023-2030 ($M)
13.1 Pediatric Market 2023-2030 ($M) - Regional Industry Research
13.2 Adult Market 2023-2030 ($M) - Regional Industry Research
14.MENA ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG Market 2023-2030 ($M)
14.1 Overvie Market 2023-2030 ($M) - Regional Industry Research
14.2 Hyper-CVAD regimen Market 2023-2030 ($M) - Regional Industry Research
14.3 Linker regimen Market 2023-2030 ($M) - Regional Industry Research
14.4 Nucleoside metabolic inhibitors Market 2023-2030 ($M) - Regional Industry Research
14.6 CALGB 8811 regimen Market 2023-2030 ($M) - Regional Industry Research
14.7 Oncaspar Market 2023-2030 ($M) - Regional Industry Research
LIST OF FIGURES
1.US Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2023-2030 ($M)2.Canada Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2023-2030 ($M)
3.Mexico Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2023-2030 ($M)
4.Brazil Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2023-2030 ($M)
5.Argentina Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2023-2030 ($M)
6.Peru Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2023-2030 ($M)
7.Colombia Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2023-2030 ($M)
8.Chile Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2023-2030 ($M)
9.Rest of South America Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2023-2030 ($M)
10.UK Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2023-2030 ($M)
11.Germany Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2023-2030 ($M)
12.France Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2023-2030 ($M)
13.Italy Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2023-2030 ($M)
14.Spain Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2023-2030 ($M)
15.Rest of Europe Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2023-2030 ($M)
16.China Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2023-2030 ($M)
17.India Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2023-2030 ($M)
18.Japan Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2023-2030 ($M)
19.South Korea Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2023-2030 ($M)
20.South Africa Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2023-2030 ($M)
21.North America Acute Lymphocytic/Lymphoblastic Leukemia By Application
22.South America Acute Lymphocytic/Lymphoblastic Leukemia By Application
23.Europe Acute Lymphocytic/Lymphoblastic Leukemia By Application
24.APAC Acute Lymphocytic/Lymphoblastic Leukemia By Application
25.MENA Acute Lymphocytic/Lymphoblastic Leukemia By Application
26.AMGEN, INC, Sales /Revenue, 2015-2018 ($Mn/$Bn)
27.BRISTOL-MYERS SQUIBB COMPANY, Sales /Revenue, 2015-2018 ($Mn/$Bn)
28.ERYTECH PHARMA, Sales /Revenue, 2015-2018 ($Mn/$Bn)
29.LEADIANT BIOSCIENCES, INC., Sales /Revenue, 2015-2018 ($Mn/$Bn)
30.NOVARTIS AG, Sales /Revenue, 2015-2018 ($Mn/$Bn)
31.PFIZER, INC, Sales /Revenue, 2015-2018 ($Mn/$Bn)
32.RARE DISEASE THERAPEUTICS, INC., Sales /Revenue, 2015-2018 ($Mn/$Bn)
33.SANOFI, Sales /Revenue, 2015-2018 ($Mn/$Bn)
34.SPECTRUM PHARMACEUTICALS, INC, Sales /Revenue, 2015-2018 ($Mn/$Bn)
35.TAKEDA PHARMACEUTICAL COMPANY LIMITED, Sales /Revenue, 2015-2018 ($Mn/$Bn)